Otsuka Pharm Co Ltd Drug Patent Portfolio
Otsuka Pharm Co Ltd owns 1 orange book drug protected by 17 US patents Given below is the list of Otsuka Pharm Co Ltd's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11648347 | Medical device containing a cake composition comprising aripiprazole as an active ingredient, and a cake composition comprising aripiprazole as an active ingredient | 06 Apr, 2034 | Active |
| US10525057 | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function | 08 Mar, 2034 | Active |
| US10980803 | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function | 24 Sep, 2033 | Active |
| US11154553 | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function | 24 Sep, 2033 | Active |
| US11344547 | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function | 24 Sep, 2033 | Active |
| US11400087 | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function | 24 Sep, 2033 | Active |
| US8399469 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof | 29 Jun, 2025 | Active |
| US8338427 | Methods for administering aripiprazole | 15 Mar, 2025 | Active |
| US7807680 | Controlled release sterile injectable aripiprazole formulation and method | 19 Oct, 2024 | Expired |
| US8030313 | Controlled release sterile injectable aripiprazole formulation and method | 19 Oct, 2024 | Expired |
| US8722679 | Controlled release sterile injectable aripiprazole formulation and method | 19 Oct, 2024 | Expired |
| US8338428 | Methods for administering aripiprazole | 06 Aug, 2023 | Expired |
| US8759351 | Methods for administering aripiprazole | 06 Aug, 2023 | Expired |
| US8993761 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof | 25 Sep, 2022 | Expired |
| US9089567 | Method of treating cognitive impairments and schizophrenias | 28 Jan, 2022 | Expired |
| US5006528 | Carbostyril derivatives | 20 Apr, 2015 | Expired |
| US5006528 | Carbostyril derivatives | 20 Apr, 2015 | Expired |
Latest Legal Activities on Otsuka Pharm Co Ltd's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Otsuka Pharm Co Ltd.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 25 Jun, 2024 | US8338428 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 25 Jun, 2024 | US8338427 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 21 Jun, 2023 | US10525057 |
|
Email Notification
Critical
| 16 May, 2023 | US11648347 |
| Patent eGrant Notification | 16 May, 2023 | US11648347 |
|
Electronic Review
Critical
| 16 May, 2023 | US11648347 |
| Recordation of Patent eGrant | 16 May, 2023 | US11648347 |
| Mail Patent eGrant Notification | 16 May, 2023 | US11648347 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 16 May, 2023 | US11648347 |
|
Recordation of Patent Grant Mailed
Critical
| 16 May, 2023 | US11648347 |
|
Expire Patent
Critical
| 08 May, 2023 | US8993761 |
|
Electronic Review
Critical
| 27 Apr, 2023 | US11648347 |
|
Email Notification
Critical
| 27 Apr, 2023 | US11648347 |
|
Issue Notification Mailed
Critical
| 26 Apr, 2023 | US11648347 |
| Dispatch to FDC | 12 Apr, 2023 | US11648347 |
Otsuka Pharm Co Ltd's Drug Patent Litigations
Otsuka Pharm Co Ltd's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jun 09, 2017, against patent number US10525057. The petitioner , challenged the validity of this patent, with Raoufinia, Arash as the respondent. Click below to track the latest information on how companies are challenging Otsuka Pharm Co Ltd's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US10525057 | June, 2017 |
Decision
(08 Mar, 2019)
| Raoufinia, Arash | |
Otsuka Pharm Co Ltd Drug Patents' Oppositions Filed in EPO
Otsuka Pharm Co Ltd drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jan 04, 2007, by Teva Pharmaceutical Industries Ltd.. This opposition was filed on patent number EP02782507A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP08000358A | May, 2017 | Bülle Dr., Jan | Revoked |
| EP08000358A | May, 2017 | Teva Pharmaceutical Industries Ltd. | Revoked |
| EP08000358A | May, 2017 | CHEMO IBERICA, S.A. | Revoked |
| EP08000358A | Apr, 2017 | Pharmaceutical Works Polpharma | Revoked |
| EP04002427A | Jan, 2011 | Teva Pharmaceutical Industries Ltd. | Patent maintained as amended |
| EP04795514A | Jul, 2009 | Alkermes, Inc. | Patent maintained as amended |
| EP02782507A | Jan, 2007 | Ratiopharm GmbH | Revoked |
| EP02782507A | Jan, 2007 | EGIS Gyógyszergyár Nyrt | Revoked |
| EP02782507A | Jan, 2007 | Pharmaceutical Works POLPHARMA | Revoked |
| EP02782507A | Jan, 2007 | Fermion Oy | Revoked |
| EP02782507A | Jan, 2007 | Teva Pharmaceutical Industries Ltd. | Revoked |
Otsuka Pharm Co Ltd's Family Patents
Otsuka Pharm Co Ltd drugs have patent protection in a total of 38 countries. It's US patent count contributes only to 25.1% of its total global patent coverage. 5 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Otsuka Pharm Co Ltd Drug List
Given below is the complete list of Otsuka Pharm Co Ltd's drugs and the patents protecting them.
1. Abilify Maintena Kit
Abilify Maintena Kit is protected by 18 patents, out of which 10 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11648347 | Medical device containing a cake composition comprising aripiprazole as an active ingredient, and a cake composition comprising aripiprazole as an active ingredient |
06 Apr, 2034
(9 years from now)
| Active |
| US10525057 | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
08 Mar, 2034
(9 years from now)
| Active |
| US10980803 | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
24 Sep, 2033
(8 years from now)
| Active |
| US11154553 | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
24 Sep, 2033
(8 years from now)
| Active |
| US11344547 | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
24 Sep, 2033
(8 years from now)
| Active |
| US11400087 | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
24 Sep, 2033
(8 years from now)
| Active |
| US8399469 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
29 Jun, 2025
(7 months from now)
| Active |
| US8338427 | Methods for administering aripiprazole |
15 Mar, 2025
(3 months from now)
| Active |
| US7807680 | Controlled release sterile injectable aripiprazole formulation and method |
19 Oct, 2024
(27 days ago)
| Expired |
| US8030313 | Controlled release sterile injectable aripiprazole formulation and method |
19 Oct, 2024
(27 days ago)
| Expired |
| US8722679 | Controlled release sterile injectable aripiprazole formulation and method |
19 Oct, 2024
(27 days ago)
| Expired |
| US8338428 | Methods for administering aripiprazole |
06 Aug, 2023
(1 year, 3 months ago)
| Expired |
| US8759351 | Methods for administering aripiprazole |
06 Aug, 2023
(1 year, 3 months ago)
| Expired |
| US8993761 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
25 Sep, 2022
(2 years ago)
| Expired |
| US9089567 | Method of treating cognitive impairments and schizophrenias |
28 Jan, 2022
(2 years ago)
| Expired |
| US5006528 | Carbostyril derivatives |
20 Apr, 2015
(9 years ago)
| Expired |
| US5006528
(Pediatric)
| Carbostyril derivatives |
20 Apr, 2015
(9 years ago)
| Expired |
| US5006528 | Carbostyril derivatives |
20 Oct, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Abilify Maintena Kit's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List